AI
QTRX icon

Atom Investors’s Quanterix QTRX Stock Holding History

Atom Investors’s Portfolio QTRX Stock Details QTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,571
Closed -$106K – 768
2025
Q3 		$106K Buy
+19,571
New +$104K 0.01% 553

Other funds holding QTRX

Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atom Investors's QTRX Position: Q4 2025 in Review

Atom Investors sold out of Quanterix (QTRX) in Q4 2025, closing a stake of 19,571 shares — an estimated $106K sold.

Atom Investors first reported a position in QTRX in Q3 2025 and held it in 1 quarter. The position peaked at $106K in Q3 2025. 134 funds tracked by Wall St. Rank hold QTRX as of Q4 2025.

  • Atom Investors reported no remaining Quanterix position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 19,571 Quanterix shares in Q4 2025, an estimated $106K.
  • Atom Investors first reported a position in Quanterix in Q3 2025 and held it in 1 quarter.
  • Atom Investors's Quanterix position peaked at $106K in Q3 2025.
  • 134 funds tracked by Wall St. Rank held Quanterix as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.